SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Equipment >

Titan Medical Inc. (TITXF)

Add TITXF Price Alert      Hide Sticky   Hide Intro
Moderator: dndodd, glg20, drrc1949, investinthefuture, cptjsd, SurgicalTechnologist
Search This Board: 
Last Post: 5/26/2017 11:37:01 PM - Followers: 261 - Board type: Free - Posts Today: 0

Titan Medical : Issued U.S. Patent Related to SPORT Surgical System Robotic Instruments

TORONTO, ON -- (Marketwired) -- 04/26/17 --  Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), announces the issuance of U.S. Patent No. 9,629,688 titled "Actuator and Drive for Manipulating a Tool," which covers the Company's unique robotic surgical instruments and in particular the novel interface and drive mechanism.

The patent generally describes a tool apparatus that includes actuators mounted in a housing in such a way to facilitate travel in a substantially orthogonal direction to the actuating direction of control links, which drive movement of the tool apparatus.

"This issuance of this patent is extremely important to Titan Medical and our development of the SPORT single port robotic surgery system, as it protects our system from would-be competitors and distinguishes our system from existing robotic technologies," said David McNally, the company's Chief Executive Officer. "In addition to the novelty of the instrument design, this patent covers key characteristics we believe will be beneficial for commercial adoption. For example, the technology was developed to provide ease of instrument loading, and it facilitates close instrument proximity when loaded in a surgical system. This is especially important for minimizing the insertion mechanism diameter and ultimately, the incision size in single-port surgery. In addition, the interface design allows for reduced tension on the instrument cables, which potentially extends the life of the reusable device."


SPORT™ Surgical System

A robotic system like no other!

The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.

Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation.

The SPORT™ Surgical System includes the following:
* a single-port surgeon controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and

* a surgeon workstation that provides the surgeon with an interface to the robotic platform   for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient’s body during MIS procedures.


David J. McNally, Chief Executive Officer, Director


Mr. McNally joins Titan after serving as the founder, President, CEO and Chairman of the Board of Domain Surgical Inc., founded in 2009, Domain is based in Salt Lake City, Utah. Mr. McNally brings substantial experience in areas of extraordinary leadership skills with all facets of building innovative medical device companies including clinically-focused product design and development, capital formation, regulatory clearance, and commercialization. Mr. McNally earned an MBA from the University of Utah, holds a Bachelor of Science degree in Mechanical Engineering from Lafayette College, Easton, PA and is the co-inventor of more than 30 U.S. and international patents associated with ferromagnetic surgical devices and systems, electromagnetic and ultrasonic sensors, and medical fluid delivery systems


                                                                                                           Surgeon Advisory Board

Vipul Patel, MD, FACS

Dr. Patel is the medical director of the Global Robotics Institute at Florida Hospital Celebration Health and medical director of the Florida Hospital Cancer Institute Urologic Oncology Program.  He is the founder of the International Prostate Cancer Foundation (IPCF) and a founding member and now president of the Society of Robotic Surgery. He serves as an honorary professor at the University of Milan, Korea University and Ricardo Palma University in Lima, Peru, and was recently made an honorary professor of the Russian Academy of Science. He is one of the most experienced robotic surgeons in the world and has personally performed over 10,000 robotic prostatectomies. Dr. Patel previously served as director of the Robotic Surgery Program at The Ohio State University in Columbus, Ohio, prior to joining Florida Hospital Celebration Heath in 2008. Dr. Patel is board certified by the American Urological Association and completed his residency and fellowship training at the University of Miami in Florida.

Arnold Advincula, MD

Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.

Juliane Bingener-Casey, MD

Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.

W. Douglas Boyd, MD

Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.

Demetrius EM Litwin, MD, MBA, FRCS, FACS, FICS

Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.

Lee L Swanstrom, MD, FACS

Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.

John Valvo, MD

Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons. 






  Patent #                                                    Title of Invention
1 8,930,027   Force Feedback System
2 8,792,688   Methods, systems and devices for three dimensional input and control methods and systems based thereon
3 8,768,509   Snaking robotic arm with movable shapers
4 8,347,754   Multi articulating robotic instrument
5 8,332,072   Robotic hand controller
6 8,306,656   Method and system for performing medical procedure
7 8,224,485   Snaking robotic arm with movable shapers
8 5,853,394   Catheter
9 5,607,407   Catheter assembly
10 4,785,868   Medical needle and method for making
  PUB. APP. NO.  Title

  24 Month Stock Performance (TMD.TO and TITXF)
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#53795  Sticky Note This current Senior Manufacturing Engineer from Microline is SurgicalTechnologist 05/14/17 09:49:48 PM
#40949  Sticky Note Titan Medical Gurufocus correct link nla 07/19/16 11:52:04 AM
#34285  Sticky Note Titan Medical Facebook Group SurgicalTechnologist 03/19/16 10:14:24 AM
#54736   You are so full of it it is glg20 05/26/17 11:37:01 PM
#54735   Ya I wouldn't listen to taco that patens Elevator777 05/26/17 10:42:36 PM
#54734   that's roughly $150/share after a 30-1 RS. RockoTaco 05/26/17 10:11:48 PM
#54733   You are probably correct but when you factor cptjsd 05/26/17 08:42:52 PM
#54732   The serious question is what are 2-3 years scalpel 05/26/17 08:26:23 PM
#54731   Probably the same as everyone else's. Call Randal posilock 05/26/17 08:25:06 PM
#54730   601 million ? cptjsd 05/26/17 07:57:13 PM
#54729   Flenderson, I might have asked this before but bet kids tuition 05/26/17 07:23:09 PM
#54728   MORE suckitup 05/26/17 07:12:16 PM
#54727   ORep8 that did not just give them away, RockoTaco 05/26/17 07:00:28 PM
#54726   Patents alone are worth $600M. RockoTaco 05/26/17 06:58:43 PM
#54725   It was just my feeling after talking with Flenderson 05/26/17 04:47:47 PM
#54724   I don't know if it's intentional, they already Flenderson 05/26/17 04:44:35 PM
#54723   I didn't get the feeling at all that Flenderson 05/26/17 04:42:46 PM
#54722   Can you elaborate on why they are so SurgicalTechnologist 05/26/17 04:39:57 PM
#54721   In Titan's defense, they are also friendly with Flenderson 05/26/17 04:30:45 PM
#54720   I don't think they could afford to purchase bobbysixty 05/26/17 04:25:10 PM
#54719   I think so too. If TRXC is going SurgicalTechnologist 05/26/17 04:24:09 PM
#54718   Didn't they essentially give them away for free?? ORrep8 05/26/17 04:22:53 PM
#54717   I think so. bobbysixty 05/26/17 04:15:12 PM
#54716   Do you think if TRXC had SPORT instead SurgicalTechnologist 05/26/17 04:14:30 PM
#54715   In all seriousness, are the patents alone even DRG1025 05/26/17 04:10:33 PM
#54714   They bought that for 100mm? Adrock 05/26/17 04:03:45 PM
#54713   What the hell are you talking about. bobbysixty 05/26/17 03:53:19 PM
#54712   Interesting that Titan's Patents and IP has kept RockoTaco 05/26/17 03:50:20 PM
#54711   Ha! "Failed Sales" let me guess, Trump Guy JMAC13 05/26/17 03:48:52 PM
#54710   1-2 units within this timeframe would categorize as bobbysixty 05/26/17 03:47:08 PM
#54709   Completely does. Sorry you don't want to believe. JMAC13 05/26/17 03:43:02 PM
#54708   1 or 2 units does not quantify as bobbysixty 05/26/17 03:40:22 PM
#54707   They do have sales tough pill to swallow. JMAC13 05/26/17 03:38:36 PM
#54706   Are you kidding me when you say "sales". bobbysixty 05/26/17 03:37:13 PM
#54705   It was sarcasm glg20 05/26/17 03:33:03 PM
#54704   All that should matter to longs is the JMAC13 05/26/17 03:31:25 PM
#54703   It would be like tying two cinder blocks DRG1025 05/26/17 03:17:59 PM
#54702   Got it. Times Yours 05/26/17 03:14:23 PM
#54701   If you say so Times Yours 05/26/17 03:13:27 PM
#54700   If you can answer, what is your belief DRG1025 05/26/17 03:11:48 PM
#54699   Oh God, heaven help us if trxc were Hypocrates 05/26/17 03:04:42 PM
#54698   I would ask them are you 100% comfortable Flenderson 05/26/17 02:54:18 PM
#54697   Microline is building the end effectors. Titan has SurgicalTechnologist 05/26/17 02:51:58 PM
#54696   I wouldn't need to see videos if the SurgicalTechnologist 05/26/17 02:49:43 PM
#54695   Yes on MDT and ISRG. We've held both hubwolf1 05/26/17 02:45:21 PM
#54694   its not all in the patents. glg20 05/26/17 02:43:39 PM
#54693   Read the information circular on SEDAR. It's all investinthefuture 05/26/17 02:43:22 PM
#54692   I don't think anyone is asking for videos. DRG1025 05/26/17 02:41:28 PM
#54691   Let's do that. Probably not smoking gun Times Yours 05/26/17 02:37:41 PM
#54690   TRXC? bobbysixty 05/26/17 01:47:27 PM
#54689   been waiting for an isrg pull back , glg20 05/26/17 01:20:07 PM
#54688   Have any of you diversified your portfolio to investinthefuture 05/26/17 01:17:22 PM
#54687   Read up on public disclosure as it pertains investinthefuture 05/26/17 01:12:22 PM